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Abstract
Background: Freezing of gait (FoG) is a common and debilitating condition in Parkinson’s disease (PD) associated
with executive dysfunction. A subtype of FoG does not respond to dopaminergic therapy and may be related to
noradrenergic deficiency. This pilot study explores the effects of atomoxetine on gait in PD patients with dopa-
unresponsive FoG using a novel paradigm for objective gait assessment.
Findings: Ten patients with PD and dopa-unresponsive FoG were enrolled in this eight-week open label pilot
study. Assessments included an exploratory gait analysis protocol that quantified spatiotemporal parameters during
straight-away walking and turning, while performing a dual task. Clinical, and subjective assessments of gait, quality
of life, and safety were also administered. The primary outcome was a validated subjective assessment for FoG
(FOG-Q). Atomoxetine was well tolerated, however, no significant change was observed in the primary outcome.
The gait analysis protocol correlated well with clinical scales, but not with subjective assessments. DBS patients
were more likely to increase gait velocity (p = 0.033), and improved in other clinical assessments.
Conclusions: Objective gait analysis protocols assessing gait while dual tasking are feasible and useful for this
patient population, and may be superior correlates of FoG severity than subjective measures. These findings can
inform future trials in this population.
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Findings
Background
Freezing of gait (FoG) is a common and disabling symp-
tom for patients with Parkinson’s disease (PD). FoG may
respond to dopaminergic therapies and DBS early in the
course, of PD, and later become dopa-unresponsive
[1, 2]. Noradrenergic deficiency has been well docu-
mented in PD and has long been proposed as a potential
etiology for FoG [3], in addition attention deficit and
executive dysfunction have also been strongly associated
with FoG [4, 5]. However, multiple trials of noradrenergic
medications have yielded conflicting results [3]. There is
currently no accepted objective measure of FoG severity.
Atomoxetine (ATM) is a norepinephrine reuptake in-
hibitor shown to improve attention deficit in adults [6]
and executive dysfunction in PD [7], with reports of
improvements in FoG [8]. In this study we explore the
effects of ATM on multiple gait parameters in patients
with PD who experience dopa-unresponsive FoG using
multiple assessments as potential outcome measures of
FoG. The purpose of this study is to gather pilot data to
be used to aid in the design of larger randomized clinical




Subjects (ages 18–80) with PD (Hoehn and Yahr stage
2–4) and dopa-unresponsive-FoG were recruited for
this study. All patients met UK-Brain Bank criteria
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for idiopathic PD, had a positive response to item 14
of the Unified Parkinson’s Disease Rating Scale (UPDRS),
and were observed to have actual FoG at screening, in the
on state. Subjects must be on stable medications for
3 months prior to starting the study, and had to be able to
walk 20 feet without an assistive device. Subjects who
were intolerant or hypersensitive to the drug class, were
on monoamine oxidase inhibitors, were demented (MMSE
< 26), whose gait dysfunction was attributable to other con-
ditions, had narrow angle glaucoma, pheochromocytoma,
severe cardiovascular conditions, uncontrolled hyperten-
sion, symptomatic tachyarrhythmias, uncontrolled depres-
sion or suicidal ideation, were excluded from the study. All
subjects underwent medical clearance prior to enrolling in
the study. The Institutional Review Board of the Medical
University of South Carolina approved the study and inves-
tigational new drug (IND) exception was granted by the
Food and Drug Administration.
Study design
This was an open-label, forced titration, 8-week study to
explore the safety, tolerability and efficacy of atomoxe-
tine for the treatment of dopa-unresponsive FoG in
patients with PD. A 3-point change in the Freezing of
Gait Questionnaire (FOG-Q) was chosen as the primary
efficacy outcome measure in order to power this pilot
study. A sample size of 10 patients treated with ato-
moxetine would have 80 % power to detect a pre-post
reduction in the mean FOG-Q score of 2.6, assuming
a standard deviation of the difference of 3.0, using a
paired t-test with a 0.05 one-sided significance level.
The estimate of the standard deviation of the change
was based on literature [9]. Exploratory efficacy outcome
measures were: changes in spatiotemporal parameters
while performing a dual cognitive task, reduction in falls,
clinical global improvement (CGI) and changes in clinical
gait outcome measures (see gait assessments). Fisher’s
exact test was used to test the null hypothesis that the
proportion of responders was the same for patients who
received DBS or did not.
All patients underwent a screening visit prior to en-
rollment. Patients who enrolled in the study were started
on 40 mg daily for two weeks then increased to 40 mg
twice daily for the 4-week treatment period. They were
then reduced to 40 mg daily for one week, and washed
out for two weeks. Full gait evaluations occurred at base-
line (Visit 2), after the 4-week treatment period at full
dose (Visit 4), and after washout (Visit 5). Visit 3 was a
safety only visit without gait assessments.
Safety and tolerability
Safety was assessed by reported adverse events, UPDRS
parts 1–4 scores, Falls Efficacy (FES) questionnaire, EKG,
vital sign assessments, and liver function tests.
Gait assessments
Gait assessments were performed in the “relative on
state” defined as 1–2 h after taking their medication,
with their DBS on (when applicable), and patient report
of feeling in the on state. The FOG-Q was administered
with each gait assessment at baseline (Visit 2), after the
4-week treatment period at full dose (Visit 4), and after
washout (Visit 5).
Clinical evaluations The Dynamic Gait Index (DGI) and
the Tinetti Gait and Balance assessments were adminis-
tered. Falls incidence and FES were also administered.
Spatiotemporal parameters All patients received brief
training regarding the protocol prior to initial assess-
ment. Subjects were asked to walk on an electronic
walkway composed of the GaitRite attached to the M2
(See Fig. 1). Each subject was instructed to stand from
a chair, walk the length of the GaitRite walkway, turn
180° on the M2 and return to the seated position at
the end of the GaitRite. Patients were then asked to
Fig. 1 Electronic Walkway Setup. The GaitRite electronic walkway
is shown here, connected to the M2 electronic walkway
demonstrating the path patients took during study procedures
to collect spatiotemporal parameters, including the turn task
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repeat this task while also performing a concurrent
cognitive task. One of two cognitive tasks was used
(serial 7’s, or alternating letters of the alphabet). Care
was taken to start at a different number or letter so
as to reduce any practice effect on the difficulty of
the cognitive task. Performance on the cognitive tasks
were rated as previously described [10].
Results
Ten patients who met all inclusion and exclusion criteria
were enrolled in the study. There were no early with-
drawals or terminations from the study. The mean age
was 67.1 years, there were eight males, and three patients
were status post bilateral subthalamic nucleus DBS.
Safety and tolerability
All ten patients tolerated the study drug well; there were
no drug discontinuation, drug dose adjustments, or
withdrawals. Seven of ten patients had eight adverse
events, all of which were mild. Three patients had mild
increases in creatine which subsided on repeat testing.
Miscellaneous reports of increase in creatine (3), wors-
ening FoG (1), diarrhea (1), worsening dyskinesia (1),
nausea (1), were recorded but resolved spontaneously,
are were not deemed clinically significant or related to
study drug. Another subject reported feeling mildly “jit-
tery” and improved after washout. This was not deemed
clinically significant but was likely related to study drug.
There were no observed increases in blood pressure,
EKG changes, palpitations, arrhythmias, or changes in
liver function. There was no change in UPDRS scores to
suggest worsening of motor symptoms.
Gait assessments
There was no significant change in the primary outcome
measure (FOG-Q) between baseline and treatment visits
in this cohort as a whole (p = 0.97). There were also no
significant changes in clinical assessments, falls inci-
dence, or CGI scores, before and after treatment (See
Table 1). As a group there was no significant change in
spatiotemporal parameters with or without concurrent
dual task performance before and after treatment (see
Table 2).
FOG-Q scores did not correlate with values for ob-
jective spatiotemporal parameters with or without con-
current dual task performance, including time to turn.
However, time to turn was highly correlated with clin-
ical measures of gait severity including: Dynamic Gait
Index (p = 0.006) and Tinetti (p = 0.012); as well as with
PD severity scales including: UPDRS motor (p = 0.02) and
total score (p = 0.056). In most instances dual tasking
improved the association further: Dynamic Gait Index
(p = 0.001), UPDRS motor (p = 0.013) and total score
(p = 0.028).
We controlled for performance on cognitive abilities
by rating their ability to perform the cognitive tasks
while walking. There was no consistent improvement or
worsening in their performance in these tasks ensuring
there was no significant practice effect and there was a
consistent difficulty level across visits.
A post-hoc analysis was performed where a subgroup
who had a greater than 0.09 m/s improvement in vel-
ocity from baseline to the post treatment visit in their
self-selected walking speed was further evaluated. This
cutoff was based on published minimal detectable change
for self-selected walking speed for PD patients [11]. Four
patients were found to have increased walking speed
based on these criteria. All three DBS “responded” and in
fact, DBS patients were more likely to have improvement
Table 1 Changes in clinical scales pre and post treatment
Baseline Post treatment Post washout
Mean SD Mean SD Mean SD
FOGQ 12.50 2.95 12.10 3.11 13.10 2.64
CGI 3.60 1.26 3.00 1.49 4.00 1.33
DGI 19.70 2.63 19.60 4.35 19.50 5.38
Tinetti 23.10 4.65 23.90 4.31 25.00 3.33
FES 31.40 19.74 23.60 16.06 24.00 13.05
PDQ39 26.40 17.41 22.31 12.83 n/a n/a
UPDRS I 2.50 3.06 2.10 2.56 1.78 2.05
UPDRS II 16.10 5.26 15.40 5.58 15.56 6.67
UPDRS III 22.80 9.95 21.70 10.57 23.90 9.78
UPDRS total 41.40 14.66 39.20 15.65 42.22 15.63
Data correspond to scores on clinical scales for gait, balance, freezing of gait,
falls, Parkinson’s symptoms, and quality of life. For all scales lower is better
except for the Tinnetti
FOG-Q Freezing of Gait Questionnaire, CGI Clinical Global Impression,
DGI Dynamic Gait Index, Tinnetti Gait and Balance, FES Falls Efficacy
Scale, PDQ-39 Parkinson’s Disease Questionnaire (quality of life measure),
UPDRS (Unified Parkinson’s Disease Rating Scale), Part I (Mentation, Behavior,
Mood), Part II (Activities of Daily Living), Part III (Motor), Part IV (Complications
from therapy)
Table 2 Changes in spatiotemporal parameters pre and post
treatment
Baseline Post treatment Post washout
Mean SD Mean SD Mean SD
Velocity 91.30 19.81 96.69 25.24 94.79 28.21
Cadence 116.4 11.56 120.78 11.09 117.24 10.99
Step length 47.62 11.55 48.77 13.51 48.42 12.85
Stride length 95.56 23.17 97.74 27.00 97.30 25.71
SST 67.43 2.24 67.49 3.16 68.65 3.83
DST 32.57 2.28 32.52 3.15 31.36 3.83
Data correspond to objective spatiotemporal parameters collected during the
“timed up and go” task, including “time to turn” as collected by the two
consecutive electronic walkways described on Fig. 1, at baseline visit (prior to
treatment with atomoxetine), Visit 4 (post treatment) and Visit 5 (post washout)
SD standard deviation, SST single support time, DST double support time
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beyond 12 cm/s in velocity (p = 0.033). Further analysis
of this subgroup revealed a decrease in FOG-Q scores
greater than 3 points (pre-specified clinically significant
change) as well as significant decreases in CGI score
(2 points) and PDQ-39 scores (12.61 points). This group
of patients also had a reduction in time to turn with and
without a concurrent cognitive task.
Conclusions
We report the results of an eight-week open label study
designed to explore the effects of atomoxetine on gait
parameters in patients with PD and dopa-unresponsive
FoG. Since dopa-unresponsive FoG is by definition not a
dopaminergic phenomenon, a noradrenergic agent was
chosen, and gait assessments were designed to capture
attention deficit and executive dysfunction by utilizing
increased cognitive load paradigms. The study did not
meet its primary endpoint of an improvement of three
points on the FOG-Q, however, important observations
were made. Atomoxetine was safe and well tolerated in
this patient population. DBS patients were more likely to
have clinically significant increases in walking speed,
FoG (as assessed by FOG-Q), time to turn while dual
tasking, and quality of life (as assessed by PDQ-39). This
may be explained by the fact that DBS patients who
have good control of other PD motor symptoms (dopa-
responsive symptoms) and still freeze provide a particu-
larly good model for the target population of this study
(dopa-unresponsive freezers).
Regarding the spatiotemporal data we report the feasi-
bility of this protocol for the quantification of gait parame-
ters, including time to turn, on two electronic walkways.
Furthermore, we found time to turn to be a strong correl-
ate of gait disturbance severity in this cohort, particularly
under the dual task condition, and found no correlation
between any of the measured objective parameters and
the FOGQ. This may be related to the subjective nature of
this measure.
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